Check out our new AlphaBind preprint demonstrating our industry-leading antibody optimization model!. Also excited to share that we have measured our BILLIONTH protein-protein interaction, providing the crucial training data to predict protein binding.

RT @DavidAYounger: Excited to share our new paper using AlphaSeq data to enable predictive ML models for antibody engineering with our wond….

RT @cangermueller: Excited to announce our latest paper on ML-guided design of single-domain antibodies against CoV-2; A collaboration betw….

RT @MadronaVentures: Don't miss our first Founded & Funded of the year! @CPicardo talks w/ @AAlphabio's @DavidAYounger about #ML in #biotec….

RT @DavidAYounger: It was a pleasure speaking with @CPicardo from @MadronaVentures about @AAlphaBio and building a company at the intersect….

RT @MadronaVentures: Applied machine/deep learning & #lifesciences are coming together to transform how we understand & improve life/health….

We’re thrilled to be part of the Top 40 Intelligent Applications created by @MadronaVentures, @PitchBook, and @GoldmanSachs. We'll celebrate next week at the #IA40 Summit sponsored by @Microsoft @Amazon.

Thank you to @frankvinluan at @medcitynews for featuring our latest collaboration with @bmsnews!. #drugdiscovery #biotech #biopharma #proteindegradation.

We are excited to announce our collaboration with Bristol Myers Squibb (@bmsnews) to discover molecular glue targets for protein degradation. Read more here:

RT @GenomeStartup: A special thank you to our alumni sponsors who participated in previous Genome Startup Day discussions & continue to sup….

A-Alpha Bio has been selected as a finalist for the annual @geekwire Awards Health Innovation of the Year! It's a fantastic honor to be recognized as a finalist and a testament to the incredible science A-Alpha Bio is doing and our company's progress.

We are very excited to announce our collaboration with @Livermore_Lab to accelerate antibody discovery for emerging COVID-19 variants by training machine learning models with binding data from AlphaSeq. Read more below!.

RT @ParseBio: We are thrilled to share we've raised $41.5M in our Series B that will grow our team and expand our product portfolio! Thanks….

As we prepare for a virtual company-wide retreat tomorrow, we can't help but reminisce on previous in-person team events and how much fun they were. looking forward to the return of more moments like these soon!

"The partnership is the first announced by A-Alpha Bio in the cutting-edge and rapidly growing area of targeted protein degradation and leverages the AlphaSeq platform to quantitatively measure protein-protein binding. " . Read more below in case you missed our exciting news!.

RT @KymeraTx: @KymeraTx is thrilled to partner with @AAlphaBio to discover and characterize novel pairs of E3 ubiquitin ligases and high-va….

(3/3).

@KymeraTx We are very excited for this first-of-its-kind program, and we couldn’t ask for a better partner in Kymera, with their track record of innovation and deep expertise in targeted protein degradation. Follow the link below to learn more about this partnership! (2/3).

We're delighted to share that we have partnered with @KymeraTx to take on the field of targeted protein degradation! Using our AlphaSeq assay, we'll identify novel interactions between high value undruggable targets and a library of E3 ubiquitin ligases to discover mol glues(1/3).

We are thrilled to announce that Padma Kodukula has joined A-Alpha Bio as Chief Business Officer! Padma will play the invaluable role of overseeing our BD strategy, with a focus on establishing and expanding key drug discovery partnerships. Read more:.